Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Interest Expenses (2021 - 2025)

Verrica Pharmaceuticals has reported Interest Expenses over the past 5 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $1.3 million for Q4 2025, down 44.06% from a year ago — trailing twelve months through Dec 2025 was $7.7 million (down 17.74% YoY), and the annual figure for FY2025 was $7.7 million, down 17.74%.
  • Interest Expenses for Q4 2025 was $1.3 million at Verrica Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Over the last five years, Interest Expenses for VRCA hit a ceiling of $2.4 million in Q3 2024 and a floor of $81000.0 in Q3 2022.
  • Median Interest Expenses over the past 5 years was $1.7 million (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Interest Expenses: crashed 92.58% in 2022 and later surged 1945.68% in 2023.
  • Verrica Pharmaceuticals' Interest Expenses stood at $1.1 million in 2021, then crashed by 92.62% to $81000.0 in 2022, then skyrocketed by 2745.68% to $2.3 million in 2023, then grew by 1.91% to $2.3 million in 2024, then plummeted by 44.06% to $1.3 million in 2025.
  • The last three reported values for Interest Expenses were $1.3 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.